UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000060721
Receipt number R000069469
Scientific Title Real world investigation of Guselukmab induction and maintenance efficacy and safety for the patients with ulcerative colitis in Japanese tertiary center : REGALIA study
Date of disclosure of the study information 2026/04/30
Last modified on 2026/04/03 04:15:36

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Real world investigation of Guselukmab induction and maintenance efficacy and safety for the patients with ulcerative colitis in Japanese tertiary center : REGALIA study

Acronym

REGALIA study

Scientific Title

Real world investigation of Guselukmab induction and maintenance efficacy and safety for the patients with ulcerative colitis in Japanese tertiary center : REGALIA study

Scientific Title:Acronym

REGALIA study

Region

Japan


Condition

Condition

ulcerative colitis

Classification by specialty

Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The purpose of this study is to establish the optimization of guselkumab treatment by prospectively examining the efficacy and safety, including the continuation rate, of guselkumab infusion and subcutaneous injection formulations in patients with ulcerative colitis.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

persistence rate at one year

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients aged 18 years or older with ulcerative colitis who are scheduled to be treated with guselkumab in our department

Key exclusion criteria

1) Patients who are allergic to guselkumab
2) Patients who are deemed inappropriate for this study by a physician

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Shingo
Middle name
Last name Kato

Organization

Saitama Medical Center, Saitama Medical University

Division name

Department of Gastroenterology and Hepatology

Zip code

350-8550

Address

1981, Kamoda, Kawagoe City, Saitama, Japan

TEL

0492283564

Email

skato@saitama-med.ac.jp


Public contact

Name of contact person

1st name Shingo
Middle name
Last name Kato

Organization

Saitama Medical Center, Saitama Medical University

Division name

Department of Gastroenterology and Hepatology

Zip code

350-8550

Address

1981, Kamoda, Kawagoe City, Saitama, Japan

TEL

0492283564

Homepage URL


Email

skato@saitama-med.ac.jp


Sponsor or person

Institute

Saitama Medical University

Institute

Department

Personal name



Funding Source

Organization

Saitama Medical University

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

IRB in Saitama Medical Center

Address

1981, Kamoda, Kawagoe City, Saitama, Japan

Tel

0492283902

Email

smcrinri@saitama-med.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2026 Year 04 Month 30 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2026 Year 04 Month 02 Day

Date of IRB

2026 Year 04 Month 02 Day

Anticipated trial start date

2026 Year 04 Month 02 Day

Last follow-up date

2030 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

nothing particular


Management information

Registered date

2026 Year 02 Month 21 Day

Last modified on

2026 Year 04 Month 03 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000069469